HRD Testing in Ovarian Cancer - What Do You Need to Consider?

In this webinar, we'll explore Homologous Recombination Deficiency (HRD) testing, addressing questions like who should have tumor tissue tested, when to conduct the testing, and what qualifies as adequate tumor tissue collection. Additionally, we'll provide an overview of our HRD Project guidelines.
Ovarian Cancer Australia has been involved in efforts to bring HRD testing to Australia since early 2022. Funded HRD testing means that more Australian women will be able to access PARP inhibitors in the future. OCA has worked alongside industry and government representatives during the approval processes, providing the voices of lived experience to each submission.